Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201045 | 0.81 | LMNA (0.50) | HPGDSMN1; SMN2TSHRPPARACNR1 | |
| SCHEMBL3374716 | 0.81 | PPARA (0.62) | POLBGAAMAPK1ABCB11CYP1A2 | |
| SCHEMBL3584331 | 0.80 | KMT2A (0.51) | HPGDSMN1; SMN2TSHRCNR1LMNA | |
| SCHEMBL199907 | 0.80 | LMNA (0.49) | HPGDSMN1; SMN2TSHRCNR1LMNA | |
| Hydrochloric Acid SCHEMBL199908 | 0.80 | LMNA (0.49) | HPGDSMN1; SMN2TSHRPPARACNR1 | |
| SCHEMBL7977777 | 0.79 | PPARA (0.68) | POLBABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3528526 | 0.77 | PPARA (0.45) | GAAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL17315771 | 0.76 | GAA (0.54) | POLBGAAHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL13750484 | 0.75 | HPGD (0.52) | POLBGAAHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL32691000 | 0.75 | POLB (0.47) | POLBGAAHPGDSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598491-B1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | CADILA HEALTHCARE LTD (IN) | 2015-09-02 | — | — | EP | disclosed |
| US-8871765-B2 | Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2014-10-28 | — | — | US | disclosed |
| EP-2598491-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | Cadila Healthcare Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014221-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2009-12-10 | — | — | US | disclosed |
| EP-1879582-A4 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1879582-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119260-A2 | COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137695-A1 | SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1-CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITORS | PARP1, PARP2, PARP11 | POLB 26/4885GAA 1680/4885HPGD 1406/4885 |
| US-20090306037-A1 | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | POLB 3886/4885GAA 1025/4885HPGD 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.